drugset / Trial / NCT07523009
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to explore the efficacy and safety of cyclosporine (CsA) combined with eltrombopag (EPAG)/hetrombopag (HPAG) and romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)
Timeline
- Start
- 2026-06
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 3 mg/kg | — |
| Subject | Cyclosporine | Peptide | 5 mg/kg | — |
| Subject | Eltrombopag | Small molecule | 150 mg | — |
| Subject | Hetrombopag | Small molecule | 15 mg | — |
| Subject | Romiplostim N01 | Peptide | 20 ug/kg | Subcutaneous |